Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medicinova (MNOV) EBITDA (2021 - 2025)

Medicinova (MNOV) has disclosed EBITDA for 8 consecutive years, with -$3.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA changed N/A to -$3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$12.0 million for FY2025, 8.34% down from the prior year.
  • EBITDA for Q4 2025 was -$3.7 million at Medicinova, down from -$3.0 million in the prior quarter.
  • The five-year high for EBITDA was -$194620.0 in Q1 2021, with the low at -$4.3 million in Q2 2021.
  • Average EBITDA over 5 years is -$2.8 million, with a median of -$2.9 million recorded in 2023.
  • The sharpest move saw EBITDA plummeted 1643.84% in 2022, then soared 80.16% in 2023.
  • Over 5 years, EBITDA stood at -$2.1 million in 2021, then tumbled by 75.28% to -$3.7 million in 2022, then skyrocketed by 43.87% to -$2.1 million in 2023, then tumbled by 38.52% to -$2.8 million in 2024, then tumbled by 31.81% to -$3.7 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$3.7 million, -$3.0 million, and -$3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.